ArticleAlzheimer's & dementia (New York, N. Y.)

Baseline plasma C1q and C3 as potential biomarkers for lecanemab efficacy and ARIA risk in early Alzheimer's disease.

Gihwan Byeon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.